Obatoclax
BCL-2 antagonist; Induces apoptosis / A novel Bcl-2 homology domain-3 (BH3) mimetic1. Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC50=0.18 μM) and induces apoptosis in primary AML cells (IC50= 3.6 μM)2. Synergizes with other agents such as chloroquine3 and cytarabine4 in cytotoxicity against a variety of cancer cells.
Biochemicals & reagents
803712-79-0
GX15-070
1) Chonghaile and Letai (2008), Mimicking the BH3 domain to kill cancer cells; Oncogene, 27 S149 2) Konopleva et al. (2008), Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res., 68 3413 3) Wang et al. (2014), Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep., 32 2789 4) Xie et al. (2015), Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol., 9 409
-20°C
TARGET: Bcl-2 -- PATHWAY: Apoptosis inducer; Proliferation; Necroptosis; Autophagy; Mitochondrial function; Bcl -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer